Vincerx Pharma enters $50M ATM equity offering agreement with Leerink Partners

Vincerx Pharma, Inc.

Up to $50M of common stock may be sold at-the-market through Leerink Partners as agent.
Commission of 3.0% of gross proceeds payable to Leerink; no obligation to sell any shares.
Sales occur under existing S-3 shelf registration (filed Jan 2022, effective Jan 2022).
Company may suspend or terminate sales at any time; either party may terminate the agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vincerx Pharma, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $50,000,000 (effective 2024-03-29).

Action: entry
Agreement: atm program
Counterparty: Leerink Partners LLC
Value: up to $50,000,000
Effective: 2024-03-29

Exact text from the filing

On March 29, 2024, Vincerx Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Sales Agent”).

View on SEC.gov

415 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-082071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.